Innoviva Earns Relative Strength Rating Upgrade – Investor's Business Daily

This article was originally published on this site

On Friday, Innoviva (INVA) earned an upgrade to its Relative Strength (RS) Rating, from 69 to 73.

X This exclusive rating from Investor’s Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating as they launch their largest runs. See if Innoviva can continue to show renewed price strength and hit that benchmark.


Looking For Winning Stocks? Try This Simple Routine


Innoviva is trying to complete a cup without handle with a 14.97 buy point. See if the stock can break out in heavy trading.

Innoviva showed 82% earnings growth in its most recent report. Sales rose 46%.

The company earns the No. 31 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals (VRTX), Sucampo Pharmaceuticals (SCMP) and Emergent Biosolutions (EBS) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock